• Dompe Group, of Milan, Italy, said the first patient has been enrolled in a Phase I/II REPARO study evaluating the ophthalmological use of a topical solution of recombinant human nerve growth factor (rhNGF) for the treatment of moderate to severe neurotrophic keratitis (NK).